

People

R & D Management changes at Exelixis

Geoffrey Duyk is to leave the position of President, R&D at Exelixis (<http://www.exelixis.com>) to follow other professional opportunities. Following Duyk's departure, effective from the end of 2003, Frank McCormack will assume a senior advisory role in the company's R&D organization. The current Senior VPs of Research (Greg Plowman), Discovery Research (Michael Morrissey) and the Chief Medical Officer (Jeffrey Latts) will continue in their positions, closely working with Duyk and McCormack to ensure a smooth transition through this management change.

George A Scangos, President and Chief Executive Officer of Exelixis, commented that: 'Geoff made a very significant contribution to the company's development and the establishment of a highly productive research and development capability and excellence in all aspects of its operations'. He went on to add that: 'Everyone at Exelixis respects and supports his choice to embark on new professional challenges at this point in his life and we wish him all the best.'

Duyk joined Exelixis from Millennium Pharmaceuticals in 1997 as one of the founding members of the scientific team. At Millennium, he was responsible for developing the informatics, automation, DNA sequencing and genotyping groups, in addition to the mouse and human genetics groups.

Management appointments at Cambridge Antibody Technology

Cambridge Antibody Technology (CAT; <http://www.cambridgeantibody.com>) has announced two senior management appointments at Vice President (VP) level.

Kathy Lambert has joined CAT as VP, Quality. She will be responsible for developing strategy and ensuring company compliance to GMP, GCP and GLP. Immediately prior to her appointment, Lambert was Director, Quality and Regulatory Affairs, for Xenova Research. Lambert has over 20 years experience in the biopharmaceutical industry.

Catherine Connolly has been appointed to VP, human resources (HR) and will take up a position on CAT's executive group. Connolly had previously been the interim HR advisor for Simpay, a communications company.

UCB Japan appoints Fabrice Egros as President

Fabrice Egros has been appointed to the position of President and Representative Director of UCB Japan (<http://www.ucb-group.com>), its Japanese subsidiary company. Prior to this appointment, Egros was VP at Sanofi-Synthelabo in the USA, where he was responsible for managed care and the strategic portfolio.

Egros was welcomed to the company by its UCB Pharma Director, Bruno Strigini, who commented: 'We are delighted that Dr Egros will join our team. Japan is an important market for UCB Pharma and his expertise and experience will add tremendous value to the implementation of our business strategy.'

UCB Pharma's headquarters are in Brussels and last year they achieved a turnover of E1.47 billion. They specialise in products aimed at allergy and respiratory diseases, and have an interest in treatments for CNS disorders.

Nick Adams promoted to Director of Business Development at Antisoma

Nick Adams has been promoted from the position of Manager, to Director of Business Development at Antisoma (<http://www.antisoma.co.uk>). Adams had held the manager's post at Antisoma since 1999 and had been successful in the negotiation of several in-licensing deals and establishing development collaborations. Most notably, Adams was a key player in the negotiations that led to the important alliance with Roche that was completed in November 2002.

Adams was appointed to the position made vacant by the departure of Bart Wuurman, who has left to join De Novo Pharmaceuticals as CEO. On Adams' appointment, Glyn Edwards, CEO Antisoma commented: 'Nick brings invaluable expertise and experience to his new role as Director of Business Development and I welcome him to our senior team. I would also like to take this opportunity to thank Bart for his excellent contribution to the company, notably his leading role in creating our alliance with Roche.'

Adams will have responsibility for the acquisition of new products to add to Antisoma's pipeline. Additionally, as a newly appointed member of the Antisoma Executive

Committee, he will be in charge of the day-to-day running of Antisoma Research Ltd, a wholly owned subsidiary of Antisoma plc.

Ichiro Shinkai joins the advisory group of Nordic Biotech

Ichiro Shinkai has joined the affiliated advisory board of Nordic Biotech, bringing with him a vast experience of the pharmaceutical industry. He has more than 20 years experience at Merck, where most recently he held the post of Senior VP in charge of all global development programmes. During this period, he has been responsible for bringing Crixivan, Fosamax, Cozaar and Hyzaar to the market. These drugs have estimated global sales in excess of US\$5 billion.

Christian Hansen, co-founder of Nordic Biotech said: 'We are proud to be able to attract such a strong calibre of international pharmaceutical leadership to the Nordic Biotech Family. Shinkai brings to us his chemical, pharmaceutical and drug development experience from decades in the global pharmaceuticals arena.'

Claes Post named as CEO of Gastrotech Pharma

Gastrotech Pharma (<http://www.gastrotech-pharma.com>) have announced the appointment of Claes Post to the position of Chief Executive Officer. Post has a strong industrial and academic background, currently as adjunct Professor of Neuropharmacology at the Karolinska Institute in Stockholm.

Previously, Post has held the position of VP Preclinical Pain and Inflammation Research at AstraZeneca and VP of Urology Development and VP of CNS at Pharmacia. He was also the start-up CEO of Melacure Therapeutics, a drug discovery company located in Uppsala.

Olle Isaksson, Chairman of the Board of Directors at Gastrotech Pharma, said: 'The addition of Post... signals a new phase of the company's development with the expected initiation of multiple clinical trials in endocrinology indications.'

Gastrotech Pharma is a newly founded company focussing on medical application of gastrointestinal hormones and was founded on the basis of research conducted at the medical faculty of Gothenburg University.

People was written by
Stephen Carney and Joanne Clough